17β-HSD10/CDK5-IN-1

Male APP/PS1 mice (6 months old) and wild-type C57BL/6 mice^[1]

10 mg/kg

i.p.; daily; 14 days

Reduced escape latency during Morris water maze training, increased time spent in the target quadrant, and increased number of platform crossings in the probe trial.
Reduced brain ROS levels in APP/PS1 mice by 41%.
Increased brain ATP levels in APP/PS1 mice by 86%.
Decreased cytochrome c levels in the cortex by 20% and in the hippocampus by 15%, returning levels close to wild-type values.
Did not significantly alter 17β-HSD10 protein expression in the cortex or hippocampus relative to the APP/PS1 model group.
Reduced hippocampal CDK5 expression by 22% relative to the APP/PS1 model group; no significant change in cortical CDK5 expression.
Reduced hippocampal p-Tau levels and hippocampal p-Tau/Tau ratio.
Increased cortical BDNF content by 76% relative to the APP/PS1 model group, reaching levels comparable to wild-type mice.
Reduced Aβ plaque burden in APP/PS1 mice to approximately one-third of the model group level.
Reduced IBA1-positive microglial activation area to approximately one-quarter of the APP/PS1 model group level, with values close to the positive control.